XTX Topco Ltd Purchases New Position in OptiNose, Inc. (NASDAQ:OPTN)

XTX Topco Ltd purchased a new position in OptiNose, Inc. (NASDAQ:OPTN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 84,504 shares of the company’s stock, valued at approximately $88,000. XTX Topco Ltd owned 0.07% of OptiNose at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. HighMark Wealth Management LLC acquired a new position in shares of OptiNose during the 1st quarter worth approximately $36,000. Oracle Investment Management Inc. purchased a new stake in OptiNose in the 1st quarter worth $474,000. Easterly Investment Partners LLC raised its position in OptiNose by 34.0% during the first quarter. Easterly Investment Partners LLC now owns 2,038,039 shares of the company’s stock worth $2,976,000 after acquiring an additional 516,730 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after purchasing an additional 81,233 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. grew its position in shares of OptiNose by 5.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company’s stock valued at $5,030,000 after purchasing an additional 200,000 shares during the period. Hedge funds and other institutional investors own 85.60% of the company’s stock.

OptiNose Stock Up 0.9 %

OPTN opened at $0.68 on Wednesday. The company has a market cap of $76.41 million, a PE ratio of -2.42 and a beta of -0.04. OptiNose, Inc. has a twelve month low of $0.65 and a twelve month high of $2.10. The company has a 50-day moving average price of $0.93 and a 200 day moving average price of $1.09.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $20.49 million for the quarter, compared to analyst estimates of $20.81 million. As a group, sell-side analysts expect that OptiNose, Inc. will post -0.22 earnings per share for the current year.

Insider Activity at OptiNose

In other OptiNose news, insider Michael F. Marino III sold 49,408 shares of OptiNose stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total transaction of $56,325.12. Following the sale, the insider now owns 550,464 shares of the company’s stock, valued at approximately $627,528.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other OptiNose news, insider Michael F. Marino III sold 49,408 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total value of $56,325.12. Following the completion of the sale, the insider now owns 550,464 shares in the company, valued at approximately $627,528.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ramy A. Mahmoud sold 111,426 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the completion of the transaction, the chief executive officer now directly owns 1,206,978 shares in the company, valued at $1,375,954.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,679 shares of company stock valued at $191,154. 2.70% of the stock is owned by insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.